CYF-VH CYSTO-NEPHRO and CYF-VHA CYSTO-NEPHRO Videoscopes - Flexible Endoscopy
Type: Capital Savings Start Date: 1 October 2023
Expiry Date: 31 January 2024
Save up to 35% when purchasing multiples of CYF-VH and CYF-VHA Videoscopes.
Olympus are delighted to offer this opportunity for customers to purchase multiples of either the CYF-VHA CYSTO-NEPHRO VIDEOSCOPE or the CYF-VH CYSTO-NEPHRO VIDEOSCOPE with major savings available.
These videoscopes give an extremely clear image while affording improved comfort to the patient.
Narrow Band Imaging (NBI) is clinically proven to allow greater detection of cancer lesions as well as being cost-effective, while the wide field of view provides a panoramic inspection area.
Features and Benefits
- High-Definition TV (HDTV) – The revolutionary CYF-VH is the first endoscope of its kind to provide a high-definition image in an endoscope this small. The crystal-clear view in the urethra improves detection and diagnosis of suspicious areas. Already under white light, the CYF-VH allows a wider view and detailed vision, which is primarily important for all bladder cancer follow-up cystoscopies.
- New Evolution Tip – In addition, the tip design improves light emittance and increases the light output by 150% (compared to the CYF-V2).
- Variable stiffness shaft – To further improve patient comfort, the CYF-VH shaft varies in stiffness. Proximally, the shaft is stiffer to keep control in the urethra. At mid-shaft, it is more flexible to minimise pressure and discomfort on sensitive anatomy. A distal passive bending section allows the scope to bend even further and minimises the potential of damage to the endoscope during normal use.
- Improved deflection – The CYF-VH bends 10° more in each direction with its 220° upward and 130° downward deflection, providing the ability to see and treat all areas of the bladder with ease.
- Large field of view – The wide 120° field of view provides a panoramic inspection of the entire bladder from the bladder neck.
- Narrow Band Imaging (NBI) – NBI allows urologists to diagnose and treat bladder cancer even more precisely and reliably. It is clinically proven that by using NBI, urologists detect more cancer lesions than by using white-light imaging (WLI). In addition, NBI is easy to handle and cost-effective. Combining all this, NBI is a safe way to improve the clinical outcomes in patients with suspected bladder cancer. NBI detects non-muscle invasive bladder cancer (NMIBC) in 17% additional patients, visualises 28% more carcinoma in situ (CIS), and increases the rate of upper urinary tract-transitional cell carcinoma (UUT-TCC) lesion detection in the kidney.
This offer is over and above the standard discount available through the NHS Supply Chain framework agreement. The discount is a fixed term offer. All orders must be placed before 31 January 2024.
For more information, please contact